Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, Westeel V, Fiteni F, Borg C, Bonnetain F. Anota A, et al. Among authors: bonnetain f. Qual Life Res. 2015 Jan;24(1):5-18. doi: 10.1007/s11136-013-0583-6. Epub 2013 Nov 26. Qual Life Res. 2015. PMID: 24277234 Free PMC article.
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.
Chibaudel B, Bonnetain F, Tournigand C, Bengrine-Lefevre L, Teixeira L, Artru P, Desramé J, Larsen AK, André T, Louvet C, de Gramont A. Chibaudel B, et al. Among authors: bonnetain f. Oncologist. 2011;16(9):1228-38. doi: 10.1634/theoncologist.2011-0039. Epub 2011 Aug 22. Oncologist. 2011. PMID: 21859820 Free PMC article. Clinical Trial.
Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer.
Hamidou Z, Dabakuyo TS, Mercier M, Fraisse J, Causeret S, Tixier H, Padeano MM, Loustalot C, Cuisenier J, Sauzedde JM, Smail M, Combier JP, Chevillote P, Rosburger C, Arveux P, Bonnetain F. Hamidou Z, et al. Among authors: bonnetain f. Oncologist. 2011;16(10):1458-68. doi: 10.1634/theoncologist.2011-0085. Epub 2011 Sep 23. Oncologist. 2011. PMID: 21948650 Free PMC article.
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, Allegra CJ, Goldberg RM, de Gramont A. Chibaudel B, et al. Among authors: bonnetain f. J Clin Oncol. 2011 Nov 1;29(31):4199-204. doi: 10.1200/JCO.2011.35.5867. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969501
Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, de Gramont A. Tournigand C, et al. Among authors: bonnetain f. J Clin Oncol. 2012 Sep 20;30(27):3353-60. doi: 10.1200/JCO.2012.42.5645. Epub 2012 Aug 20. J Clin Oncol. 2012. PMID: 22915656
Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study.
Hebbar M, Chibaudel B, André T, Louvet C, Smith D, Mineur L, Bennamoun M, Mabro M, Brusquant D, Bonnetain F, Pruvot FR, de Gramont A. Hebbar M, et al. Among authors: bonnetain f. J Chemother. 2013 Apr;25(2):104-11. doi: 10.1179/1973947812Y.0000000048. J Chemother. 2013. PMID: 23684358 Clinical Trial.
253 results